Solid Lung Nodules Found in 42% of Non-Smokers
“A new study of more than 10,000 non-smoking adults found that solid lung nodules were present in a considerable portion of study participants. Non-smokers are traditionally thought to be at low risk for lung nodules and lung cancer. The results of the study were published today in Radiology, a journal of the Radiological Society of North America (RSNA).”
Comparative long-term prognosis of early surgery and surgery after surveillance for patients with ground-glass nodule adenocarcinomas
“To compare the pathological results and long-term survival results of early surgery and surgery after at least one year follow-up for ground‐glass component predominant lung adenocarcinoma patients. From January 1, 2013 to August 31, 2017, a total of 279 patients with ground-glass nodules (GGNs) undergoing surgical resection and pathologically proved to be pulmonary adenocarcinoma were included in this study.”
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
“AUSTIN, Texas, Aug. 14, 2024 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced positive clinical study updates for its Acclaim-1 and Acclaim-3 clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), respectively, and plans to re-focus its oncology clinical development program.”
Imfinzi granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
“AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), based on the results from the positive ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy (cCRT), has been accepted and granted Priority Review in the US.”
Homotypic cell-in-cell structure as a novel prognostic predictor in non-small cell lung cancer and frequently localized at the invasive front
“Homotypic cell-in-cell structures (hoCICs) are associated with tumor proliferation, invasion, and metastasis and is considered a promising prognostic marker in various cancers. However, the role of hoCICs in non-small cell lung cancer (NSCLC) remains unclear.”
Polypharmacy May Shorten Survival in Lung Cancer
“Older patients with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy treatment tended to have worse survival outcomes if they were taking five or more other oral or inhaled medications, according to a study published in the Journal of Geriatric Oncology.”
What to know about small cell lung cancer and pneumonia
“Small cell lung cancer (SCLC) may increase the risk of pneumonia due to a weakened immune system or structural changes to the lungs.”
First Patient Enrolled in ON-SITE Study of AI-Based Image Analysis for Lung Cancer Detection
“The ON-SITE study has enrolled its first patient. This multicenter investigation will explore the effectiveness of an artificial intelligence (AI)-based image analysis module for lung cancer detection.”
Climate Change And Lung Cancer: Pollution A Major Cause Of Lung Cancer In Non-smokers
“Lung Cancer In Non-smokers: A recent report by The Lancet under the title ‘Lung cancer in Asia: the impact of climate change’ highlights the growing number of lung cancer in non-smokers. The study is a testimony to the already catastrophic impact of climate crisis the world is witnessing. Numerous conferences and events are organized to address the challenge of climate crises that costs a huge lump of money. However, only a few challenges are given priority and effective measures. Rising pollution in cities is a sheer sight of climate change and its adverse effect. However, it is still not given the prominence it deserves and demands.”
Video:
Harrisburg mom takes to TikTok to chronicle lung cancer journey and empower others
Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC
“Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.”
Dr. Carbone on the Importance of Biomarker Testing for Patients With Lung Cancer
“David P. Carbone, MD, PhD, director of the James Thoracic Oncology Center at The Ohio State University Comprehensive Cancer Center, discusses the importance of biomarker testing for patients with lung cancer.”
